Acumen Pharmaceuticals (ABOS) Stifel 2024 Healthcare Conference summary

Program overview and clinical progress

• Advancing sabirnetug, a next-generation monoclonal antibody targeting Aβ oligomers for early Alzheimer's disease, with robust safety and biomarker engagement shown in phase I-B data.

• Phase II Altitude AD study includes two active doses versus placebo, enrolling 540 patients with primary outcome at 18 months using iADRS.

• Enrollment has outpaced expectations, with completion anticipated in the first half of 2025 and data readout projected for late 2026.

• Strong phase I results and innovative study design have attracted top investigators and rapid patient uptake.

• Subcutaneous (subQ) formulation in development, with phase I results expected in early 2025 to inform future clinical strategy.

Industry landscape and strategic positioning

• Alzheimer's treatment landscape is evolving, with infrastructure and system readiness gradually improving for broader adoption.

• Multiple products and targets are expected to coexist, with ongoing innovation in diagnostics and biomarkers enhancing patient access and treatment selection.

• Recent strategic deals, such as AbbVie's acquisition of Aliada, reflect Big Pharma's confidence in Aβ strategies and external innovation.

• Enhanced brain delivery technologies and blood-brain barrier techniques are seen as promising for improving efficacy and safety profiles.

• The field is drawing parallels to the early days of MS treatments, with growing subspecialization and interest among neurologists and other clinicians.

Biomarker innovation and clinical trial design

• Use of plasma pTau217 as a screening tool has halved negative PET scans, reducing costs and patient burden.

• Consistent biomarker changes across synaptic and inflammatory markers reinforce confidence in the target and agent.

• The biomarker field is rapidly evolving, with plans to bank samples for future analysis as new markers emerge.

• Phase II is designed as a registration-quality study, with no interim analysis planned to preserve data integrity and regulatory value.

• Success will be judged on the totality of clinical and biomarker data, not just p-values, to inform phase III design and dose selection.